AngioDynamics, Inc. (NASDAQ: ANGO) and Immunophotonics, Inc. are pleased to announce a partnership that will combine use of Immunophotonics’ lead clinical asset, IP-001, and AngioDynamics’ ablation devices to explore the power of ablation in combination with immunotherapy for the treatment of solid tumor cancers.
